Weekly Health Update | Two Ebola Vaccine Candidates Recommended for DRC Trial; Nigeria and Kenya Monitor Contacts
The WHO is evaluating two new vaccine candidates for clinical trials to combat the Bundibugyo Ebola virus in the DRC. Meanwhile, Nigeria and Kenya are actively monitoring contacts to prevent the spread of the disease.
Why it matters
Public health efforts to contain Ebola outbreaks are critical for regional stability and preventing global health crises.
email facebook linkedin twitter Whatsapp Two additional vaccine candidates could join clinical trials against the Bundibugyo virus responsible for the Ebola outbreak in the Democratic Republic of Congo (DRC). Nigeria and Kenya continue to monitor cases and contacts, while the World Health Organization (WHO) assesses emergency preparedness in Liberia and Mozambique. Kenya is also expanding efforts to track early childhood development.
DRC: Two New Ebola Vaccine Candidates Proposed for Clinical Trial
WHO is accelerating vaccine research against the Bundibugyo virus. With the outbreak in the DRC exceeding 10,500 confirmed cases and more than 5,100 deaths as of November 1, two additional vaccine candidates could join the Tumaini clinical trial, subject to approval by Congolese authorities.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in